03200nas a2200265 4500008004100000245012900041210006900170260001900239300001200258490000600270520234400276653002702620653002202647653001802669653001502687653002102702653001102723653001702734100002502751700002402776700001702800700002202817700002902839856006602868 2019 eng d00aThe Economic Outcomes of Pharmacist Interventions at Critical Care Services of Private Hospital in Riyadh City, Saudi Arabia0 aEconomic Outcomes of Pharmacist Interventions at Critical Care S cSeptember 2019 aS23-S340 v53 a

Objectives: The study aims to explore the economic outcomes of the clinical pharmacist at critical care units at a private hospital in Riyadh city, Saudi Arabia in a 6 month study and prevent additional medication costs. Methods: It was a 6-months cross-sectional study from January to June 2016 in adults critical care unit. It was a thirty-bed critical care bed consisting of trauma, medical, surgical and maternity critical care cases. The pharmacist monitored all patients through daily medical round and documents any pharmacist intervention. The pharmacist intervention system used an international study model, measure level of activity, rational of clinical intervention, recommendation, patient outcome and pharmacoeconomic impact related estimated cost avoidance. Results: The total number of pharmacist interventions were (1,222) provided to (1,124) patients. The complete cost avoidance from pharmacist intervention over the study period was (220,882.10 UD) while over one year was (441,764.2 USD). The highest cost avoidance of critical care interventions was from potentially significant 51.00% (102,581.78 USD) and potentially serious 32.28% (99,162.29 USD). The majority of cost avoidance came from anti-infective agents (73,408.95 USD) followed by nutrition and blood agents (61,182.97 USD) and cardiovascular medications (27,584.52 USD). The most rational clinical activities cost avoidance was from others type (102,168.44 USD) followed by inappropriate dose (30,504.16 USD) and TPN consultations (25,313.99 USD). The most patient outcome related to cost avoidance was patient condition improved (120,036.38 USD) followed by unknown outcomes (47,067.85 USD) and laboratory values improved (21,661.55 USD). The most pharmacoeconomic cost avoidance impact was a reduction in the cost drug therapy 79.94% (163,747.96 USD) and the patient length of hospital stay decreased 1.15% (32,846.49 USD). Conclusion: The critical care clinical pharmacist prevent the additional cost of drugrelated problems occurrences and economic burden on the healthcare system at a private hospital in the Kingdom of Saudi Arabia. Expanding clinical pharmacist at critical care services is highly recommended to all private hospitals in Saudi Arabia.

10aCritical care services10aEconomic outcomes10aInterventions10aPharmacist10aPrivate hopsital10aRiyadh10aSaudi Arabia1 aAlomi, Yousef, Ahmed1 aEl-Bahnasawi, Manal1 aElemam, Alaa1 aShaweesh, Tasneem1 aAntonio, Edmarie, Janine uhttps://www.ptbreports.org/article/2019/5/3s/105530ptb2019534